Yahoo
NasdaqCM - Nasdaq Real Time Price USD

ENDRA Life Sciences Inc. (NDRA)

4.7500 -0.1300 (-2.66%)
At close: October 30 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for NDRA
  • Previous Close 4.8800
  • Open 4.8500
  • Bid 4.2900 x 200
  • Ask 7.5200 x 200
  • Day's Range 4.7225 - 4.8600
  • 52 Week Range 2.9600 - 6.9500
  • Volume 10,517
  • Avg. Volume 31,143
  • Market Cap (intraday) 7.125M
  • Beta (5Y Monthly) -0.11
  • PE Ratio (TTM) --
  • EPS (TTM) -6.2600
  • Earnings Date (est.) --
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 25.00
  • Zacks Rating Neutral

ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is involved in the development of thermo-acoustic enhanced ultrasound technology that uses pulsed energy source such as radio frequency to transmit energy deep into tissue and generate ultrasonic waves to create high-contrast images for use in the treatment of non-alcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion analysis. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.

endrainc.com

9

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

NDRA
4.86%
S&P 500 (^GSPC)
10.73%

1-Year Return

NDRA
2.66%
S&P 500 (^GSPC)
11.11%

3-Year Return

NDRA
99.71%
S&P 500 (^GSPC)
81.91%

5-Year Return

NDRA
99.99%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue --
Earnings 159.94k
Profit Margin 0.00%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

-3M
-2M
-1M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

25.00
25.00 Average
4.7500 Current
25.00 High

Latest Rating

Date 6/1/2026
Analyst Ascendiant Capital
Rating Action Maintains
Rating Buy
Price Action Lowers
Price Target 27 -> 25

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -77.32%

  • Return on Equity (ttm)

    -152.04%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -5.92M

  • Diluted EPS (ttm)

    -6.2600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    1.74M

  • Total Debt/Equity (mrq)

    6.80%

  • Levered Free Cash Flow (ttm)

    -6.73M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: